Biomarkers for Alzheimer’s disease. Where we stand and where we are headed

Biomarcadores de enfermedad de Alzheimer. Dónde estamos y hacia dónde vamos. La enfermedad de Alzheimer (EA) es uno de los mayores flagelos aún no resueltos que acompañan al aumento de la expectativa de vida. El gran cambio de paradigma en los últimos años fue consecuencia de descubrir que el depósi...

Full description

Autores:
Chrem Mendez, Patricio
Surace, Ezequiel
Bérgamo, Yanina
Calandri, Ismael
Vázquez, Silvia
Sevlever, Gustavo
Allegri, Ricardo Francisco
Tipo de recurso:
Article of journal
Fecha de publicación:
2019
Institución:
Corporación Universidad de la Costa
Repositorio:
REDICUC - Repositorio CUC
Idioma:
spa
OAI Identifier:
oai:repositorio.cuc.edu.co:11323/7372
Acceso en línea:
https://hdl.handle.net/11323/7372
https://repositorio.cuc.edu.co/
Palabra clave:
biomarcadores de la enfermedad de Alzheimer
etapas preclínicas
neuroimágenes
diagnóstico molecular
Rights
openAccess
License
Attribution-NonCommercial-NoDerivatives 4.0 International
id RCUC2_fef4745d9e62757bb5afdeeea9f69c84
oai_identifier_str oai:repositorio.cuc.edu.co:11323/7372
network_acronym_str RCUC2
network_name_str REDICUC - Repositorio CUC
repository_id_str
dc.title.spa.fl_str_mv Biomarkers for Alzheimer’s disease. Where we stand and where we are headed
dc.title.translated.spa.fl_str_mv Biomarcadores de enfermedad de Alzheimer. Dónde estamos y hacia dónde vamos
title Biomarkers for Alzheimer’s disease. Where we stand and where we are headed
spellingShingle Biomarkers for Alzheimer’s disease. Where we stand and where we are headed
biomarcadores de la enfermedad de Alzheimer
etapas preclínicas
neuroimágenes
diagnóstico molecular
title_short Biomarkers for Alzheimer’s disease. Where we stand and where we are headed
title_full Biomarkers for Alzheimer’s disease. Where we stand and where we are headed
title_fullStr Biomarkers for Alzheimer’s disease. Where we stand and where we are headed
title_full_unstemmed Biomarkers for Alzheimer’s disease. Where we stand and where we are headed
title_sort Biomarkers for Alzheimer’s disease. Where we stand and where we are headed
dc.creator.fl_str_mv Chrem Mendez, Patricio
Surace, Ezequiel
Bérgamo, Yanina
Calandri, Ismael
Vázquez, Silvia
Sevlever, Gustavo
Allegri, Ricardo Francisco
dc.contributor.author.spa.fl_str_mv Chrem Mendez, Patricio
Surace, Ezequiel
Bérgamo, Yanina
Calandri, Ismael
Vázquez, Silvia
Sevlever, Gustavo
dc.contributor.author.none.fl_str_mv Allegri, Ricardo Francisco
dc.subject.spa.fl_str_mv biomarcadores de la enfermedad de Alzheimer
etapas preclínicas
neuroimágenes
diagnóstico molecular
topic biomarcadores de la enfermedad de Alzheimer
etapas preclínicas
neuroimágenes
diagnóstico molecular
description Biomarcadores de enfermedad de Alzheimer. Dónde estamos y hacia dónde vamos. La enfermedad de Alzheimer (EA) es uno de los mayores flagelos aún no resueltos que acompañan al aumento de la expectativa de vida. El gran cambio de paradigma en los últimos años fue consecuencia de descubrir que el depósito amiloideo se presenta hasta 20 años antes, y la degeneración neurofibrilar hasta 10 años antes, de que aparezca la sintomatología clínica típica de pérdida de memoria. La aparición de los biomarcadores permitió reestructurar el concepto de la EA, intentándose llegar a una definición molecular de la misma casi prescindiendo de la emblemática clínica. Existen distintos tipos de biomarcadores de EA disponibles en nuestro país. Cada uno nos habla de un proceso y un momento distinto de la enfermedad. Aunque su uso clínico aún se encuentra restringido por cuestiones de costos, existen escenarios particulares en donde sí se justifica, casi siempre en relación a presentaciones clínicas atípicas o de comienzo muy temprano. Sin embargo, hoy en día ya nadie discute que son imprescindibles en investigaciones clínicas sobre EA. La incorporación de biomarcadores en la práctica médica ha generado cambios significativos en la intervención terapéutica de los pacientes, incluso en un contexto en el que todavía no hay medicamentos modificadores de la enfermedad.
publishDate 2019
dc.date.issued.none.fl_str_mv 2019
dc.date.accessioned.none.fl_str_mv 2020-11-19T19:44:22Z
dc.date.available.none.fl_str_mv 2020-11-19T19:44:22Z
dc.type.spa.fl_str_mv Artículo de revista
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_6501
dc.type.content.spa.fl_str_mv Text
dc.type.driver.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.redcol.spa.fl_str_mv http://purl.org/redcol/resource_type/ART
dc.type.version.spa.fl_str_mv info:eu-repo/semantics/acceptedVersion
format http://purl.org/coar/resource_type/c_6501
status_str acceptedVersion
dc.identifier.uri.spa.fl_str_mv https://hdl.handle.net/11323/7372
dc.identifier.instname.spa.fl_str_mv Corporación Universidad de la Costa
dc.identifier.reponame.spa.fl_str_mv REDICUC - Repositorio CUC
dc.identifier.repourl.spa.fl_str_mv https://repositorio.cuc.edu.co/
url https://hdl.handle.net/11323/7372
https://repositorio.cuc.edu.co/
identifier_str_mv Corporación Universidad de la Costa
REDICUC - Repositorio CUC
dc.language.iso.none.fl_str_mv spa
language spa
dc.relation.references.spa.fl_str_mv 1. World Health Organization and Alzheimer’s Disease International. Dementia: a public health priority. In: https:// www.who.int/mental_health/publications/dementia_report_2012/en/; accessed March 2019.
2. Allegri RF, Vázquez S, Sevlever G. Enfermedad de Alzheimer: Nuevos paradigmas, 2da. ed. Buenos Aires: Editorial Polemos, 2018.
3. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 2012; 367: 795-804.
4. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939-44.
5. Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 257-62.
6. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on AgingAlzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 270-9.
7. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 263-9.
8. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 280-92.
9. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018; 14: 535-62.
10. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-34.
11. Niikado M, Chrem-Méndez P, Itzcovich T, et al. Evaluation of cerebrospinal fluid neurofilament light chain as a routine biomarker in a memory clinic. J Gerontol A Biol Sci Med Sci 2019; 74: 442-5.
12. Hampel H, O’Bryant SE, Molinuevo JL, et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol 2018; 14: 639-52.
13. Hampel H, Vergallo A, Perry G, Lista S. The Alzheimer Precision Medicine Initiative. Alzheimer Precision Medicine Initiative (APMI). J Alzheimers Dis 2019; 68: 1-24.
14. Preische O, Schultz SA, Apel A, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat Med 2019; 25: 277-83.
15. Veitcha DP, Weiner MW, Aiseng PS, et al. Understanding disease progression and improving Alzheimer’s disease clinical trials: Recent highlights from the Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Dement 2019; 15: 106-52.
16. Buckner RL, Andrews-Hanna JR, Schacter DL. The brain´s default network: anatomy, function, and relevance to disease. Ann NY Acad Sci 2008; 1124: 1-38.
17. Allegri RF, Pertierra L, Cohen G, et al. A biological classification for Alzheimer’s disease - Amyloid, Tau and Neurodegeneration (A/T/N): results from the ArgentineAlzheimer’s Disease Neuroimaging Initiative. Int Psychogeriatr 2019; 12: 1-2.
18. Parra MA, Baez S, Allegri R, et al. Dementia in Latin America: Assessing the present and envisioning the future. Neurology 2018; 90: 222-31.
19. Chrem Méndez P, Cohen G, Russo MJ, et al. Concordance between 11C-PIB-PET and clinical diagnosis in a memory clinic. Am J Alzheimers Dis Other Demen 2015; 30: 599- 606.
20. Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA 2019; 321: 1286-94.
dc.rights.spa.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.uri.spa.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.accessrights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.coar.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv Corporación Universidad de la Costa
dc.source.spa.fl_str_mv MEDICINA (Buenos Aires)
institution Corporación Universidad de la Costa
dc.source.url.spa.fl_str_mv http://www.medicinabuenosaires.com/PMID/31864224.pdf
bitstream.url.fl_str_mv https://repositorio.cuc.edu.co/bitstreams/c03245ff-3890-433d-9e19-221cabbe0572/download
https://repositorio.cuc.edu.co/bitstreams/2c4bc104-38b1-4d8f-915e-5ef76a588591/download
https://repositorio.cuc.edu.co/bitstreams/1cda3550-aa5c-4694-a929-c56670227dc9/download
https://repositorio.cuc.edu.co/bitstreams/6c98d3af-d097-4277-bcaa-a67ed7f74b16/download
https://repositorio.cuc.edu.co/bitstreams/a107d1da-3666-4c4e-a737-c0b6c04742b3/download
bitstream.checksum.fl_str_mv e1bf59fc8eec0b7d82fa862e2b6ec7f3
4460e5956bc1d1639be9ae6146a50347
e30e9215131d99561d40d6b0abbe9bad
e956773ece1ca74597650289568a16f9
229afea906883892c672ac15a0d4496d
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio de la Universidad de la Costa CUC
repository.mail.fl_str_mv repdigital@cuc.edu.co
_version_ 1828166836962721792
spelling Chrem Mendez, PatricioSurace, EzequielBérgamo, YaninaCalandri, IsmaelVázquez, SilviaSevlever, GustavoAllegri, Ricardo Franciscovirtual::801-12020-11-19T19:44:22Z2020-11-19T19:44:22Z2019https://hdl.handle.net/11323/7372Corporación Universidad de la CostaREDICUC - Repositorio CUChttps://repositorio.cuc.edu.co/Biomarcadores de enfermedad de Alzheimer. Dónde estamos y hacia dónde vamos. La enfermedad de Alzheimer (EA) es uno de los mayores flagelos aún no resueltos que acompañan al aumento de la expectativa de vida. El gran cambio de paradigma en los últimos años fue consecuencia de descubrir que el depósito amiloideo se presenta hasta 20 años antes, y la degeneración neurofibrilar hasta 10 años antes, de que aparezca la sintomatología clínica típica de pérdida de memoria. La aparición de los biomarcadores permitió reestructurar el concepto de la EA, intentándose llegar a una definición molecular de la misma casi prescindiendo de la emblemática clínica. Existen distintos tipos de biomarcadores de EA disponibles en nuestro país. Cada uno nos habla de un proceso y un momento distinto de la enfermedad. Aunque su uso clínico aún se encuentra restringido por cuestiones de costos, existen escenarios particulares en donde sí se justifica, casi siempre en relación a presentaciones clínicas atípicas o de comienzo muy temprano. Sin embargo, hoy en día ya nadie discute que son imprescindibles en investigaciones clínicas sobre EA. La incorporación de biomarcadores en la práctica médica ha generado cambios significativos en la intervención terapéutica de los pacientes, incluso en un contexto en el que todavía no hay medicamentos modificadores de la enfermedad.Alzheimer disease (AD) is one of the major unresolved health burdens accompanying the increase in life expectancy. The great paradigm shift for this disease has resulted from finding amyloid deposition and neurobrillary degeneration 20 years and 10 years, respectively, prior to onset of the typical clinical memory loss symptoms. The advent of AD biomarkers has enabled a molecular definition of AD, making the clinical definition almost dispensable. Various types of AD biomarkers are available in our country. Each biomarker reflects a particular process and stage of the disease. Although costs restrict their use, the biomarker analysis may be justified in certain clinical scenarios, such as an early onset or an atypical presentation of the disease. Today, the usefulness of biomarkers in AD clinical research is beyond question. Furthermore, the introduction of biomarkers into medical practice has led to significant changes in therapeutic interventions, even in the absence of disease-modifying drugs.Chrem Mendez, Patricio-will be generated-orcid-0000-0002-6790-6566-600Surace, Ezequiel-will be generated-orcid-0000-0001-8492-9578-600Bérgamo, YaninaCalandri, IsmaelVázquez, SilviaSevlever, Gustavo-will be generated-orcid-0000-0002-9567-7553-600Allegri, Ricardo Francisco-will be generated-orcid-0000-0001-7166-1234-600application/pdfspaCorporación Universidad de la CostaAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2MEDICINA (Buenos Aires)http://www.medicinabuenosaires.com/PMID/31864224.pdfbiomarcadores de la enfermedad de Alzheimeretapas preclínicasneuroimágenesdiagnóstico molecularBiomarkers for Alzheimer’s disease. Where we stand and where we are headedBiomarcadores de enfermedad de Alzheimer. Dónde estamos y hacia dónde vamosArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/acceptedVersion1. World Health Organization and Alzheimer’s Disease International. Dementia: a public health priority. In: https:// www.who.int/mental_health/publications/dementia_report_2012/en/; accessed March 2019.2. Allegri RF, Vázquez S, Sevlever G. Enfermedad de Alzheimer: Nuevos paradigmas, 2da. ed. Buenos Aires: Editorial Polemos, 2018.3. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 2012; 367: 795-804.4. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939-44.5. Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 257-62.6. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on AgingAlzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 270-9.7. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 263-9.8. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 280-92.9. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018; 14: 535-62.10. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-34.11. Niikado M, Chrem-Méndez P, Itzcovich T, et al. Evaluation of cerebrospinal fluid neurofilament light chain as a routine biomarker in a memory clinic. J Gerontol A Biol Sci Med Sci 2019; 74: 442-5.12. Hampel H, O’Bryant SE, Molinuevo JL, et al. Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nat Rev Neurol 2018; 14: 639-52.13. Hampel H, Vergallo A, Perry G, Lista S. The Alzheimer Precision Medicine Initiative. Alzheimer Precision Medicine Initiative (APMI). J Alzheimers Dis 2019; 68: 1-24.14. Preische O, Schultz SA, Apel A, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat Med 2019; 25: 277-83.15. Veitcha DP, Weiner MW, Aiseng PS, et al. Understanding disease progression and improving Alzheimer’s disease clinical trials: Recent highlights from the Alzheimer’s Disease Neuroimaging Initiative. Alzheimers Dement 2019; 15: 106-52.16. Buckner RL, Andrews-Hanna JR, Schacter DL. The brain´s default network: anatomy, function, and relevance to disease. Ann NY Acad Sci 2008; 1124: 1-38.17. Allegri RF, Pertierra L, Cohen G, et al. A biological classification for Alzheimer’s disease - Amyloid, Tau and Neurodegeneration (A/T/N): results from the ArgentineAlzheimer’s Disease Neuroimaging Initiative. Int Psychogeriatr 2019; 12: 1-2.18. Parra MA, Baez S, Allegri R, et al. Dementia in Latin America: Assessing the present and envisioning the future. Neurology 2018; 90: 222-31.19. Chrem Méndez P, Cohen G, Russo MJ, et al. Concordance between 11C-PIB-PET and clinical diagnosis in a memory clinic. Am J Alzheimers Dis Other Demen 2015; 30: 599- 606.20. Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA 2019; 321: 1286-94.Publication3a5e2fdd-48ee-4d8e-acc4-3119bbdc1a17virtual::801-13a5e2fdd-48ee-4d8e-acc4-3119bbdc1a17virtual::801-1https://scholar.google.com/citations?user=-SIKk2UAAAAJ&hl=esvirtual::801-10000-0001-7166-1234virtual::801-1ORIGINALBIOMARKERS FOR ALZHEIMER´S DISEASE. WHERE WE STAND AND WHERE WE ARE HEADED.pdfBIOMARKERS FOR ALZHEIMER´S DISEASE. WHERE WE STAND AND WHERE WE ARE HEADED.pdfapplication/pdf1032082https://repositorio.cuc.edu.co/bitstreams/c03245ff-3890-433d-9e19-221cabbe0572/downloade1bf59fc8eec0b7d82fa862e2b6ec7f3MD51CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8805https://repositorio.cuc.edu.co/bitstreams/2c4bc104-38b1-4d8f-915e-5ef76a588591/download4460e5956bc1d1639be9ae6146a50347MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-83196https://repositorio.cuc.edu.co/bitstreams/1cda3550-aa5c-4694-a929-c56670227dc9/downloade30e9215131d99561d40d6b0abbe9badMD53THUMBNAILBIOMARKERS FOR ALZHEIMER´S DISEASE. WHERE WE STAND AND WHERE WE ARE HEADED.pdf.jpgBIOMARKERS FOR ALZHEIMER´S DISEASE. WHERE WE STAND AND WHERE WE ARE HEADED.pdf.jpgimage/jpeg65124https://repositorio.cuc.edu.co/bitstreams/6c98d3af-d097-4277-bcaa-a67ed7f74b16/downloade956773ece1ca74597650289568a16f9MD54TEXTBIOMARKERS FOR ALZHEIMER´S DISEASE. WHERE WE STAND AND WHERE WE ARE HEADED.pdf.txtBIOMARKERS FOR ALZHEIMER´S DISEASE. WHERE WE STAND AND WHERE WE ARE HEADED.pdf.txttext/plain25108https://repositorio.cuc.edu.co/bitstreams/a107d1da-3666-4c4e-a737-c0b6c04742b3/download229afea906883892c672ac15a0d4496dMD5511323/7372oai:repositorio.cuc.edu.co:11323/73722025-02-24 08:49:28.577http://creativecommons.org/licenses/by-nc-nd/4.0/Attribution-NonCommercial-NoDerivatives 4.0 Internationalopen.accesshttps://repositorio.cuc.edu.coRepositorio de la Universidad de la Costa CUCrepdigital@cuc.edu.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

Publicaciones similares